Quarterly Result19 Aug 2025, 10:01 pm
Gujarat Themis Biosyn Ltd Reports Strong FY2024-25 Performance, Announces AGM and Capital Expenditure Plan
AI Summary
Gujarat Themis Biosyn Ltd has reported a strong financial performance for the fiscal year 2024-25, with revenues of Rs. 150.8 crores, EBITDA of Rs. 68.8 crores, and PAT of Rs. 48.8 crores. The company has maintained production levels despite market volatility and power disruptions. GTBL is planning to expand its product portfolio with new intermediates and APIs, driven by its capital expenditure plan, which includes the commissioning of a new R&D facility, a dedicated API block, and additional fermentation capacity.
Key Highlights
- Gujarat Themis Biosyn Ltd reports strong FY2024-25 performance with Rs. 150.8 crores in revenue.
- Company maintains production levels despite market volatility and power disruptions.
- GTBL plans to expand product portfolio with new intermediates and APIs.
- Capital expenditure plan includes commissioning of new R&D facility, dedicated API block, and additional fermentation capacity.
- Company announces 44th AGM to be held on 12th September, 2025.